RTTNews | Dec 11, 2021 10:26AM EST

10:26 Saturday, December 11, 2021 (RTTNews.com) - Epizyme Inc. (EPZM) said that data presented from both in vitro and in vivo preclinical studies, demonstrated that targeting SETD2 with EZM0414 resulted in significantly reduced growth of t(4;14) multiple myeloma cell lines, as well as non-t(4;14) multiple myeloma and diffuse large B-cell lymphoma cell lines.

Additionally, in in vitro studies, EZM0414 showed synergy with multiple myeloma and diffuse large B-cell lymphoma standard of care and emerging therapies, which supports the potential for the study of EZM0414 in combination with current multiple myeloma and diffuse large B-cell lymphoma treatments.

Epizyme shared the preclinical data and the Phase 1/1b trial design for EZM0414, the company's novel, first-in-class, oral SETD2 inhibitor, an investigational agent being developed for the treatment of adult patients with relapsed or refractory multiple myeloma or with diffuse large B-cell lymphoma (DLBCL). The data and the design were presented Sarturday at the 2021 American Society of Hematology (ASH) Annual Meeting.

Read the original article on RTTNews ( https://www.rttnews.com/3248594/epizyme-preclinical-data-shows-its-setd2-inhibitor-ezm0414-reduced-growth-of-mm-dlbcl-cell-lines.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved